In Vivo CRO Market Size, Share & Trends Report

In Vivo CRO Market Size, Share & Trends Analysis Report By Model Type (Rodent Based, Non-rodent Based), By Modality (Small Molecule, Large Molecule), By Indication, By GLP Type (Non GLP, GLP Toxicology), By Region, And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-1-68038-011-8
  • Number of Pages: 257
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2023
  • Industry: Healthcare

Table of Contents

Chapter 1. In Vivo CRO Market: Methodology and Scope
                   1.1. Market Segmentation & Scope
                   1.2. Segment Definitions
                       1.2.1. Model Type
                       1.2.2. Modality
                       1.2.3. Indication
                       1.2.4. GLP Type
                       1.2.5. Regional scope
                       1.2.6. Estimates and forecasts timeline
                   1.3. Research Methodology
                   1.4. Information Procurement
                       1.4.1. Purchased database
                       1.4.2. GVR’s internal database
                       1.4.3. Secondary sources
                       1.4.4. Primary research
                       1.4.5. Details of primary research
                           1.4.5.1. Data for primary interviews in North America
                           1.4.5.2. Data for primary interviews in Europe
                           1.4.5.3. Data for primary interviews in Asia Pacific
                           1.4.5.4. Data for primary interviews in Latin America
                           1.4.5.5. Data for Primary interviews in MEA
                   1.5. Information or Data Analysis
                       1.5.1. Data analysis models
                   1.6. Market Formulation & Validation
                   1.7. Model Details
                       1.7.1. Commodity flow analysis (Model 1)
                       1.7.2. Approach 1: Commodity flow approach
                       1.7.3. Volume price analysis (Model 2)
                       1.7.4. Approach 2: Volume price analysis
                   1.8. List of Secondary Sources
                   1.9. List of Primary Sources
                   1.10. Objectives
Chapter 2. In Vivo CRO Market: Executive Summary
                   2.1. Market Outlook
                   2.2. Segment Outlook
                       2.2.1. Model type outlook
                       2.2.2. Modality outlook
                       2.2.3. Indication outlook
                       2.2.4. GLP type outlook
                       2.2.5. Regional outlook
                   2.3. Competitive Insights
Chapter 3. In Vivo CRO Market: Variables, Trends & Scope
                   3.1. Market Lineage Outlook
                       3.1.1. Parent market outlook
                       3.1.2. Related/ancillary market outlook
                   3.2. Market Dynamics
                       3.2.1. Market driver analysis
                           3.2.1.1. Changing regulatory landscape
                           3.2.1.2. Increase in offshoring medical device manufacturing to emerging countries
                           3.2.1.3. Rising demand for advanced products
                           3.2.1.4. Implementation of international standards by contract manufacturers
                           3.2.1.5. Rising price competition and requirement to reduce cost
                           3.2.1.6. Increasing complexity concerning product design and engineering
                       3.2.2. Market restraint analysis
                           3.2.2.1. Compliance issues while outsourcing
                           3.2.2.2. Changing scenarios in developing countries
                           3.2.2.3. Regulatory and legal compliance
                           3.2.2.4. Contractual obligation
                   3.3. In Vivo CRO Market Analysis Tools
                       3.3.1. Industry Analysis - Porter’s
                           3.3.1.1. Supplier power
                           3.3.1.2. Buyer power
                           3.3.1.3. Substitution threat
                           3.3.1.4. Threat of new entrant
                           3.3.1.5. Competitive rivalry
                       3.3.2. PESTEL Analysis
                           3.3.2.1. Political landscape
                           3.3.2.2. Technological landscape
                           3.3.2.3. Economic landscape
                       3.3.3. Pricing Analysis
Chapter 4. In Vivo CRO Market: Model Type Estimates & Trend Analysis
                   4.1. Model Type Market Share, 2023 & 2030
                   4.2. Segment Dashboard
                   4.3. Global In Vivo CRO Market by Model Type Outlook
                   4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                       4.4.1. Rodent based
                           4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           4.4.1.2. Rat models
                               4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           4.4.1.3. Mice models
                               4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           4.4.1.4. Others
                               4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       4.4.2. Non-rodent based
                           4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. In Vivo CRO Market: Modality Estimates & Trend Analysis
                   5.1. Modality Market Share, 2023 & 2030
                   5.2. Segment Dashboard
                   5.3. Global In Vivo CRO Market by Modality Outlook
                   5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                       5.4.1. Small molecules
                           5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.2. Large molecules
                           5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           5.4.2.2. Cell & gene therapy
                               5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               5.4.2.2.2. CAR T-cell therapies
                                   5.4.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               5.4.2.2.3. CAR-NK cell therapies
                                   5.4.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               5.4.2.2.4. TCR-T cell therapies
                                   5.4.2.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               5.4.2.2.5. Other (Includes- TCR-NK, CARM, and TAC-T)
                                   5.4.2.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.3. RNA therapy
                           5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.4. Others
                           5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. In Vivo CRO Market: Indication Estimates & Trend Analysis
                   6.1. Indication Market Share, 2023 & 2030
                   6.2. Segment Dashboard
                   6.3. Global In Vivo CRO Market by Indication Outlook
                   6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                       6.4.1. Oncology
                           6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.1.2. Blood cancer
                               6.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.1.3. Solid tumor
                               6.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               6.4.1.3.2. Solid tumor
                                   6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                                   6.4.1.3.2.2. Syngeneic model
                                       6.4.1.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                                   6.4.1.3.2.3. Patient derived xenograft
                                       6.4.1.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                                   6.4.1.3.2.4. Xenograft
                                       6.4.1.3.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                               6.4.1.3.3. Others
                                   6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       6.4.2. CNS conditions
                           6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.2.2. Epilepsy
                               6.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.2.3. Parkinson's disease
                               6.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.2.4. Huntington's disease
                               6.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.2.5. Stroke
                               6.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.2.6. Muscular dystrophy
                               6.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.2.7. Alzheimer’s disease
                               6.4.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.2.8. Traumatic brain injury
                               6.4.2.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.2.9. Amyotrophic lateral sclerosis (ALS)
                               6.4.2.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.2.10. Spinal muscular atrophy
                               6.4.2.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.2.11. Muscle regeneration
                               6.4.2.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.2.12. Other neurodevelopment disorders
                               6.4.2.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       6.4.3. Diabetes
                           6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       6.4.4. Obesity
                           6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       6.4.5. Pain management
                           6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.5.2. Chronic pain
                               6.4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.5.3. Chronic pain
                               6.4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       6.4.6. Autoimmune/inflammation conditions
                           6.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.6.2. Rheumatoid arthritis
                               6.4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.6.3. Multiple sclerosis
                               6.4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.6.4. Osteoarthritis
                               6.4.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.6.5. Irritable bowel syndrome
                               6.4.6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.6.6. Others
                               6.4.6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       6.4.7. Others
                           6.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. In Vivo CRO Market: GLP Type Estimates & Trend Analysis
                   7.1. GLP Type Market Share, 2023 & 2030
                   7.2. Segment Dashboard
                   7.3. Global In Vivo CRO Market by GLP Type Outlook
                   7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                       7.4.1. GLP toxicology
                           7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       7.4.2. Non GLP
                           7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. In Vivo CRO Market: Regional Estimates & Trend Analysis
                   8.1. Regional Market Share Analysis, 2023 & 2030
                   8.2. Regional Market Dashboard
                   8.3. Global Regional Market Snapshot
                   8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
                   8.5. North America
                       8.5.1. U.S.
                           8.5.1.1. Key country dynamics
                           8.5.1.2. Regulatory framework/ reimbursement structure
                           8.5.1.3. Competitive scenario
                           8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
                       8.5.2. Canada
                           8.5.2.1. Key country dynamics
                           8.5.2.2. Regulatory framework/ reimbursement structure
                           8.5.2.3. Competitive scenario
                           8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
                   8.6. Europe
                       8.6.1. UK
                           8.6.1.1. Key country dynamics
                           8.6.1.2. Regulatory framework/ reimbursement structure
                           8.6.1.3. Competitive scenario
                           8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
                       8.6.2. Germany
                           8.6.2.1. Key country dynamics
                           8.6.2.2. Regulatory framework/ reimbursement structure
                           8.6.2.3. Competitive scenario
                           8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
                       8.6.3. France
                           8.6.3.1. Key country dynamics
                           8.6.3.2. Regulatory framework/ reimbursement structure
                           8.6.3.3. Competitive scenario
                           8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
                       8.6.4. Italy
                           8.6.4.1. Key country dynamics
                           8.6.4.2. Regulatory framework/ reimbursement structure
                           8.6.4.3. Competitive scenario
                           8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
                       8.6.5. Spain
                           8.6.5.1. Key country dynamics
                           8.6.5.2. Regulatory framework/ reimbursement structure
                           8.6.5.3. Competitive scenario
                           8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
                       8.6.6. Norway
                           8.6.6.1. Key country dynamics
                           8.6.6.2. Regulatory framework/ reimbursement structure
                           8.6.6.3. Competitive scenario
                           8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
                       8.6.7. Sweden
                           8.6.7.1. Key country dynamics
                           8.6.7.2. Regulatory framework/ reimbursement structure
                           8.6.7.3. Competitive scenario
                           8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
                       8.6.8. Denmark
                           8.6.8.1. Key country dynamics
                           8.6.8.2. Regulatory framework/ reimbursement structure
                           8.6.8.3. Competitive scenario
                           8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
                   8.7. Asia Pacific
                       8.7.1. Japan
                           8.7.1.1. Key country dynamics
                           8.7.1.2. Regulatory framework/ reimbursement structure
                           8.7.1.3. Competitive scenario
                           8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
                       8.7.2. China
                           8.7.2.1. Key country dynamics
                           8.7.2.2. Regulatory framework/ reimbursement structure
                           8.7.2.3. Competitive scenario
                           8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
                       8.7.3. India
                           8.7.3.1. Key country dynamics
                           8.7.3.2. Regulatory framework/ reimbursement structure
                           8.7.3.3. Competitive scenario
                           8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
                       8.7.4. Australia
                           8.7.4.1. Key country dynamics
                           8.7.4.2. Regulatory framework/ reimbursement structure
                           8.7.4.3. Competitive scenario
                           8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
                       8.7.5. South Korea
                           8.7.5.1. Key country dynamics
                           8.7.5.2. Regulatory framework/ reimbursement structure
                           8.7.5.3. Competitive scenario
                           8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
                       8.7.6. Thailand
                           8.7.6.1. Key country dynamics
                           8.7.6.2. Regulatory framework/ reimbursement structure
                           8.7.6.3. Competitive scenario
                           8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
                   8.8. Latin America
                       8.8.1. Brazil
                           8.8.1.1. Key country dynamics
                           8.8.1.2. Regulatory framework/ reimbursement structure
                           8.8.1.3. Competitive scenario
                           8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
                       8.8.2. Mexico
                           8.8.2.1. Key country dynamics
                           8.8.2.2. Regulatory framework/ reimbursement structure
                           8.8.2.3. Competitive scenario
                           8.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
                       8.8.3. Argentina
                           8.8.3.1. Key country dynamics
                           8.8.3.2. Regulatory framework/ reimbursement structure
                           8.8.3.3. Competitive scenario
                           8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
                   8.9. MEA
                       8.9.1. South Africa
                           8.9.1.1. Key country dynamics
                           8.9.1.2. Regulatory framework/ reimbursement structure
                           8.9.1.3. Competitive scenario
                           8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
                       8.9.2. Saudi Arabia
                           8.9.2.1. Key country dynamics
                           8.9.2.2. Regulatory framework/ reimbursement structure
                           8.9.2.3. Competitive scenario
                           8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
                       8.9.3. UAE
                           8.9.3.1. Key country dynamics
                           8.9.3.2. Regulatory framework/ reimbursement structure
                           8.9.3.3. Competitive scenario
                           8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
                       8.9.4. Kuwait
                           8.9.4.1. Key country dynamics
                           8.9.4.2. Regulatory framework/ reimbursement structure
                           8.9.4.3. Competitive scenario
                           8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
                   9.1. Recent Developments & Impact Analysis, By Key Market Participants
                   9.2. Company/Competition Categorization
                   9.3. Vendor Landscape
                       9.3.1. List of key distributors and channel partners
                       9.3.2. Key customers
                       9.3.3. Key company market share analysis, 2023
                       9.3.4. IQVIA Inc.
                           9.3.4.1. Company overview
                           9.3.4.2. Financial performance
                           9.3.4.3. Product benchmarking
                           9.3.4.4. Strategic initiatives
                       9.3.5. Crown Bioscience
                           9.3.5.1. Company overview
                           9.3.5.2. Financial performance
                           9.3.5.3. Product benchmarking
                           9.3.5.4. Strategic initiatives
                       9.3.6. Taconic Biosciences, Inc.
                           9.3.6.1. Company overview
                           9.3.6.2. Financial performance
                           9.3.6.3. Product benchmarking
                           9.3.6.4. Strategic initiatives
                       9.3.7. PsychoGenics Inc.
                           9.3.7.1. Company overview
                           9.3.7.2. Financial performance
                           9.3.7.3. Product benchmarking
                           9.3.7.4. Strategic initiatives
                       9.3.8. Evotec
                           9.3.8.1. Company overview
                           9.3.8.2. Financial performance
                           9.3.8.3. Product benchmarking
                           9.3.8.4. Strategic initiatives
                       9.3.9. Janvier Labs
                           9.3.9.1. Company overview
                           9.3.9.2. Financial performance
                           9.3.9.3. Product benchmarking
                           9.3.9.4. Strategic initiatives
                       9.3.10. Biocytogen Boston Corp
                           9.3.10.1. Company overview
                           9.3.10.2. Financial performance
                           9.3.10.3. Product benchmarking
                           9.3.10.4. Strategic initiatives
                       9.3.11. GemPharmatech
                           9.3.11.1. Company overview
                           9.3.11.2. Financial performance
                           9.3.11.3. Product benchmarking
                           9.3.11.4. Strategic initiatives
                       9.3.12. Charles River Laboratories
                           9.3.12.1. Company overview
                           9.3.12.2. Financial performance
                           9.3.12.3. Product benchmarking
                           9.3.12.4. Strategic initiatives
                       9.3.13. Icon Plc
                           9.3.13.1. Company overview
                           9.3.13.2. Financial performance
                           9.3.13.3. Product benchmarking
                           9.3.13.4. Strategic initiatives
                       9.3.14. Labcorp Drug Development
                           9.3.14.1. Company overview
                           9.3.14.2. Financial performance
                           9.3.14.3. Product benchmarking
                           9.3.14.4. Strategic initiatives
                       9.3.15. Parexel International Corporation
                           9.3.15.1. Company overview
                           9.3.15.2. Financial performance
                           9.3.15.3. Product benchmarking
                           9.3.15.4. Strategic initiatives
                       9.3.16. SMO Clinical Research (I) Pvt Ltd.
                           9.3.16.1. Company overview
                           9.3.16.2. Financial performance
                           9.3.16.3. Product benchmarking
                           9.3.16.4. Strategic initiatives


List of Tables

Table 1 List of abbreviation
Table 2 North America in vivo CRO market, by region, 2018 - 2030 (USD Million)
Table 3 North America in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 4 North America in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 5 North America in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 6 North America in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 7 U.S. in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 8 U.S. in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 9 U.S. in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 10 U.S. in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 11 Canada in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 12 Canada in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 13 Canada in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 14 Canada in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 15 Europe in vivo CRO market, by region, 2018 - 2030 (USD Million)
Table 16 Europe in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 17 Europe in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 18 Europe in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 19 Europe in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 20 Germany in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 21 Germany in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 22 Germany in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 23 Germany in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 24 UK in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 25 UK in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 26 UK in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 27 UK in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 28 France in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 29 France in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 30 France in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 31 France in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 32 Italy in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 33 Italy in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 34 Italy in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 35 Italy in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 36 Spain in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 37 Spain in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 38 Spain in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 39 Spain in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 40 Denmark in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 41 Denmark in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 42 Denmark in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 43 Denmark in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 44 Sweden in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 45 Sweden in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 46 Sweden in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 47 Sweden in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 48 Norway in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 49 Norway in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 50 Norway in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 51 Norway in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 52 Asia Pacific in vivo CRO market, by region, 2018 - 2030 (USD Million)
Table 53 Asia Pacific in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 54 Asia Pacific in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 55 Asia Pacific in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 56 Asia Pacific in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 57 China in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 58 China in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 59 China in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 60 China in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 61 Japan in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 62 Japan in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 63 Japan in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 64 Japan in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 65 India in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 66 India in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 67 India in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 68 India in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 69 South Korea in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 70 South Korea in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 71 South Korea in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 72 South Korea in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 73 Australia in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 74 Australia in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 75 Australia in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 76 Australia in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 77 Thailand in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 78 Thailand in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 79 Thailand in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 80 Thailand in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 81 Latin America in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 82 Latin America in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 83 Latin America in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 84 Latin America in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 85 Brazil in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 86 Brazil in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 87 Brazil in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 88 Brazil in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 89 Mexico in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 90 Mexico in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 91 Mexico in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 92 Mexico in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 93 Argentina in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 94 Argentina in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 95 Argentina in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 96 Argentina in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 97 MEA in vivo CRO market, by region, 2018 - 2030 (USD Million)
Table 98 MEA in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 99 MEA in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 100 MEA in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 101 MEA in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 102 South Africa in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 103 South Africa in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 104 South Africa in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 105 South Africa in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 106 Saudi Arabia in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 107 Saudi Arabia in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 108 Saudi Arabia in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 109 Saudi Arabia in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 110 UAE in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 111 UAE in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 112 UAE in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 113 UAE in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
Table 114 Kuwait in vivo CRO market, by model type, 2018 - 2030 (USD Million)
Table 115 Kuwait in vivo CRO market, by modality, 2018 - 2030 (USD Million)
Table 116 Kuwait in vivo CRO market, by indication, 2018 - 2030 (USD Million)
Table 117 Kuwait in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)


List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 In vivo CRO market: market outlook
Fig. 14 In vivo CRO competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 In vivo CRO market driver impact
Fig. 20 In vivo CRO market restraint impact
Fig. 21 In vivo CRO market strategic initiatives analysis
Fig. 22 In vivo CRO market: Model type movement analysis
Fig. 23 In vivo CRO market: Model type outlook and key takeaways
Fig. 24 Rodent based market estimates and forecast, 2018 - 2030
Fig. 25 Rat models estimates and forecast, 2018 - 2030
Fig. 26 Mice Models market estimates and forecast, 2018 - 2030
Fig. 27 Others estimates and forecast, 2018 - 2030
Fig. 28 Non-rodent based market estimates and forecast, 2018 - 2030
Fig. 29 In vivo CRO Market: Modality movement Analysis
Fig. 30 In vivo CRO market: Modality outlook and key takeaways
Fig. 31 Small molecules market estimates and forecasts, 2018 - 2030
Fig. 32 Large molecules market estimates and forecasts,2018 - 2030
Fig. 33 Cell & gene therapy market estimates and forecasts,2018 - 2030
Fig. 34 CAR T-cell therapies market estimates and forecasts, 2018 - 2030
Fig. 35 CAR-NK cell therapy market estimates and forecasts, 2018 - 2030
Fig. 36 TCR-T cell therapy market estimates and forecasts, 2018 - 2030
Fig. 37 Other (Includes- TCR-NK, CARM, and TAC-T) market estimates and forecasts, 2018 - 2030
Fig. 38 RNA therapy market estimates and forecasts, 2018 - 2030
Fig. 39 Others market estimates and forecasts, 2018 - 2030
Fig. 40 In vivo CRO market: Indication movement analysis
Fig. 41 In vivo CRO market: Indication outlook and key takeaways
Fig. 42 Oncology market estimates and forecasts, 2018 - 2030
Fig. 43 Blood cancer market estimates and forecasts,2018 - 2030
Fig. 44 Solid tumor market estimates and forecasts, 2018 - 2030
Fig. 45 Syngeneic model market estimates and forecasts,2018 - 2030
Fig. 46 Syngeneic model market estimates and forecasts, 2018 - 2030
Fig. 47 Xenograft market estimates and forecasts,2018 - 2030
Fig. 48 Others market estimates and forecasts,2018 - 2030
Fig. 49 CNS conditions market estimates and forecasts,2018 - 2030
Fig. 50 Epilepsy market estimates and forecasts,2018 - 2030
Fig. 51 Parkinson's disease market estimates and forecasts,2018 - 2030
Fig. 52 Huntington's disease market estimates and forecasts,2018 - 2030
Fig. 53 Stroke market estimates and forecasts,2018 - 2030
Fig. 54 Muscular dystrophy market estimates and forecasts,2018 - 2030
Fig. 55 Alzheimer’s disease market estimates and forecasts,2018 - 2030
Fig. 56 Traumatic brain injury market estimates and forecasts,2018 - 2030
Fig. 57 Amyotrophic lateral sclerosis (ALS) market estimates and forecasts,2018 - 2030
Fig. 58 Spinal muscular atrophy market estimates and forecasts,2018 - 2030
Fig. 59 Muscle regeneration market estimates and forecasts,2018 - 2030
Fig. 60 Other neurodevelopment disorders market estimates and forecasts,2018 - 2030
Fig. 61 Diabetes market estimates and forecasts,2018 - 2030
Fig. 62 Obesity market estimates and forecasts,2018 - 2030
Fig. 63 Pain management market estimates and forecasts,2018 - 2030
Fig. 64 Chronic pain market estimates and forecasts,2018 - 2030
Fig. 65 Acute pain market estimates and forecasts,2018 - 2030
Fig. 66 Autoimmune/inflammation conditions market estimates and forecasts,2018 - 2030
Fig. 67 Rheumatoid arthritis market estimates and forecasts,2018 - 2030
Fig. 68 Multiple sclerosis market estimates and forecasts,2018 - 2030
Fig. 69 Osteoarthritis market estimates and forecasts,2018 - 2030
Fig. 70 Irritable bowel syndrome market estimates and forecasts,2018 - 2030
Fig. 71 Others market estimates and forecasts,2018 - 2030
Fig. 72 Others market estimates and forecasts,2018 - 2030
Fig. 73 Global in vivo CRO market: Regional movement analysis
Fig. 74 Global in vivo CRO market: Regional outlook and key takeaways
Fig. 75 Global in vivo CRO market share and leading players
Fig. 76 North America market share and leading players
Fig. 77 Europe market share and leading players
Fig. 78 Asia Pacific market share and leading players
Fig. 79 Latin America market share and leading players
Fig. 80 Middle East & Africa market share and leading players
Fig. 81 North America, by country
Fig. 82 North America
Fig. 83 North America market estimates and forecasts, 2018 - 2030
Fig. 84 U.S.
Fig. 85 U.S. market estimates and forecasts, 2018 - 2030
Fig. 86 Canada
Fig. 87 Canada market estimates and forecasts, 2018 - 2030
Fig. 88 Europe
Fig. 89 Europe market estimates and forecasts, 2018 - 2030
Fig. 90 UK
Fig. 91 UK market estimates and forecasts, 2018 - 2030
Fig. 92 Germany
Fig. 93 Germany market estimates and forecasts, 2018 - 2030
Fig. 94 France
Fig. 95 France market estimates and forecasts, 2018 - 2030
Fig. 96 Italy
Fig. 97 Italy market estimates and forecasts, 2018 - 2030
Fig. 98 Spain
Fig. 99 Spain market estimates and forecasts, 2018 - 2030
Fig. 100 Denmark
Fig. 101 Denmark market estimates and forecasts, 2018 - 2030
Fig. 102 Sweden
Fig. 103 Sweden market estimates and forecasts, 2018 - 2030
Fig. 104 Norway
Fig. 105 Norway market estimates and forecasts, 2018 - 2030
Fig. 106 Asia Pacific
Fig. 107 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 108 China
Fig. 109 China market estimates and forecasts, 2018 - 2030
Fig. 110 Japan
Fig. 111 Japan market estimates and forecasts, 2018 - 2030
Fig. 112 India
Fig. 113 India market estimates and forecasts, 2018 - 2030
Fig. 114 Thailand
Fig. 115 Thailand market estimates and forecasts, 2018 - 2030
Fig. 116 South Korea
Fig. 117 South Korea market estimates and forecasts, 2018 - 2030
Fig. 118 Australia
Fig. 119 Australia market estimates and forecasts, 2018 - 2030
Fig. 120 Latin America
Fig. 121 Latin America market estimates and forecasts, 2018 - 2030
Fig. 122 Brazil
Fig. 123 Brazil market estimates and forecasts, 2018 - 2030
Fig. 124 Mexico
Fig. 125 Mexico market estimates and forecasts, 2018 - 2030
Fig. 126 Argentina
Fig. 127 Argentina market estimates and forecasts, 2018 - 2030
Fig. 128 Middle East and Africa
Fig. 129 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 130 South Africa
Fig. 131 South Africa market estimates and forecasts, 2018 - 2030
Fig. 132 Saudi Arabia
Fig. 133 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 134 UAE
Fig. 135 UAE market estimates and forecasts, 2018 - 2030
Fig. 136 Kuwait
Fig. 137 Kuwait market estimates and forecasts, 2018 - 2030
Fig. 138 Market share of key market players- In vivo CRO market

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon